Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1/2 3Phase 1 1

Status

Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 9Other solid neoplasm 4Head & Neck 4Gastrointestinal 4Genitourinary 2Dermatologic 2CNS 2Tumor-Agnostic 1Gynecologic 1Breast 1

Conditions

Colorectal Neoplasms 2Stomach Neoplasms 1Spinocerebellar Degenerations 1Rectal Neoplasms 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Tiragolumab × Gastrointestinal × Clear all
NCT05009069 2026-04-21

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Hoffmann-La Roche

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Rectal Neoplasms

NCT06603818 2026-02-19

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT06784947 2025-10-02

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

University of Colorado, Denver

Phase 2 Active not recruiting
13 enrolled
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Hoffmann-La Roche

Phase 2 Terminated
29 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡